Neonatal abstinence syndrome — assessment and dyad care (MEQ)

(i) Definition and contributors. NAS is a postnatal withdrawal syndrome after in-utero dependence-forming exposures; NOWS specifies primarily opioid-driven withdrawal. This infant’s risk is driven by methadone OAT (expected, not proof of maltreatment), with modifiers: tobacco, possible benzodiazepine contribution, and the postnatal environment. Distinguish from FASD (teratogenic spectrum, not this acute withdrawal picture). Timing at ~36 h is compatible with evolving opioid withdrawal; methadone can still peak later, so continued observation matters.[2][3][7]

(ii) Assessment and differentials. Structured serial assessment with Finnegan-type scores and/or Eat-Sleep-Console function (feed, sleep ~1 h, consolability). Full observations: vitals, weight, intake/output, skin. Do not miss: sepsis, hypoglycaemia, electrolyte disturbance from diarrhoea, neurologic disease. Here afebrile + normal glucose is reassuring but recheck if deterioration. Inventory maternal substances, verify methadone dose with clinic, document social risks without weaponising care. Toxicology only with consent/clinical purpose.[2][3][4][7]

(iii) Management ladder. First-line non-pharmacologic: rooming-in, parental presence, low stimulation, swaddling, skin-to-skin, clustered cares, feeding support — QI data show this reduces morphine use and LOS versus historic threshold-only cultures.[8] Escalate to protocol oral opioids (unit morphine/methadone/buprenorphine pathways) if function fails despite optimised supportive care or if severe features (seizures, severe GI losses) appear; adjuncts (clonidine/phenobarbital) only under specialist protocols for refractory/polysubstance phenotypes. Wean when stable; discharge when feeding/weight and parental competence allow.[2][3][7]

(iv) Counselling dyad and safeguarding. Methadone did not “damage” the baby in the FASD sense — it treated maternal OUD and likely reduced illicit-use harms; NAS is expected and treatable.[6] Do not stop OAT as punishment; abrupt cessation raises maternal relapse/overdose risk postpartum. Breastfeeding is generally supported if she remains stable on methadone, not using illicit drugs, and infection pathways allow (HCV: breastfeeding usually not contraindicated solely by HCV Ab; follow local BBV guidance; HIV pathways differ). Formula is acceptable if she prefers or contraindications exist. Child protection: prior file warrants risk-based collaborative planning (supports, kinship options if needed) — NAS after therapeutic OAT alone is not automatic permanent removal.[3][6][7]

(v) Evidence names. MOTHER (Jones 2010): buprenorphine vs methadone — lower neonatal treatment burden with buprenorphine but higher maternal discontinuation. Suarez 2022: large cohort favouring several neonatal outcomes with buprenorphine vs methadone. Young ESC 2023: shorter time to medical readiness vs usual care. Grossman QI: supportive-care redesign reduces morphine and LOS. ACOG/AAP: maintain maternal OAT; plan neonatal monitoring.[1][4][5][6][8]